MOUNTAIN VIEW, Calif. — NeuroPace Inc. reported new long-term clinical data supporting its RNS System for epilepsy, highlighting sustained seizure reduction in patients with drug-resistant forms of the condition.
The company said results from a three-year post-approval study, published in the journal Neurology, showed a median seizure reduction of 82% in adults with drug-resistant focal epilepsy, reinforcing the device’s effectiveness in real-world settings.
The study enrolled 324 patients across 32 U.S. centers, making it the largest FDA-reviewed prospective neuromodulation study for this type of epilepsy.
NeuroPace also presented new data from its ongoing NAUTILUS trial at the 2026 American Academy of Neurology annual meeting, focusing on patients with idiopathic generalized epilepsy who do not respond to medication.
Results from that study showed a 77% median reduction in generalized tonic-clonic seizures at 18 months, along with improvements across other seizure types. The company said injury rates declined by about 30% following treatment, while the need for rescue medications dropped by 44% compared with baseline.
“The publication of the 3-year PAS results in Neurology represents an important milestone for the epilepsy community and adds to the robust body of evidence supporting the RNS System in drug-resistant focal epilepsy,” said Martha Morrell, M.D., chief medical officer of NeuroPace. “At the same time, the NAUTILUS dataset continues to mature, and we remain encouraged by the durability of the treatment effect and safety profile observed to date in idiopathic generalized epilepsy. These data highlight the broad potential of responsive neurostimulation to address meaningful unmet needs across epilepsy populations.”
Chief Executive Officer Joel Becker said the findings reflect the company’s broader effort to expand the use of its technology.
“NeuroPace continues to lead the field in developing high-quality clinical evidence for neuromodulation in epilepsy,” Becker said. “The publication of our 3-year PAS results in Neurology and the presentation of NAUTILUS data at AAN reflect the depth of our evidence base and our commitment to advancing the RNS System across both established and emerging patient populations.”
The RNS System uses responsive neurostimulation to detect abnormal brain activity and deliver targeted electrical stimulation aimed at preventing seizures. The new data add to a growing body of evidence supporting its use in both focal and generalized epilepsy populations.
